Improved neurocognitive test performance in both arms of the SMART study: Impact of practice effect

Journal of NeuroVirology

Volumn 19, Issue 4, 2013, Pages 383-392

  Grund, Birgit ^a   Wright, Edwina J ^b,c   Brew, Bruce J ^d,e   Price, Richard W ^f   Roediger, Mollie P ^a   Bain, Margaret P ^d   Hoy, Jennifer F ^b   Shlay, Judith C ^g   Vjecha, Michael J ^h   Robertson, Kevin R ⁱ  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DENVER PUBLIC HEALTH   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Learning effect; Neurocognitive performance; Neuropsychological tests; Practice effect; Test retest

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; AUSTRALIA; BRAZIL; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TASK PERFORMANCE; THAILAND;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LEARNING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 84883480239     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-013-0190-x     Document Type: Article

References (43)

1. Al-Khindi T, Zakzanis KK, van Gorp WG (2011) Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature. J Int Neuropsychol Soc 17:956-969
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789-1799
3. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K, Collaboration C (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neur 63:213-221
4. Brouwers P, Hendricks M, Lietzau JA, Pluda JM, Mitsuya H, Broder S, Yarchoan R (1997) Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS 11:59-66
5. Carvalhal AS, Rourke SB, Belmonte-Abreu P, Correa J, Goldani LZ (2006) Evaluation of neuropsychological performance of HIV-infected patients with minor motor cognitive dysfunction treated with highly active antiretroviral therapy. Infection 34:357-360
6. Chang L, Ernst T, Witt MD, Ames N, Walot I, Jovicich J, DeSilva M, Trivedi N, Speck O, Miller EN (2003) Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 8:17-26
7. Childers ME, Woods SP, Letendre S, McCutchan JA, Rosario D, Grant I, Mindt MR, Ellis RJ, San Diego HIV Neurobehavioral Research Center Group (2008) Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J Neurovirol 14:550-557
8. Cysique LA, Franklin D, Abramson I, Ellis RJ, Letendre S, Collier A, Clifford D, Gelman B, McArthur J, Morgello S, Simpson D, McCutchan JA, Grant I, Heaton RK, Grp C, Grp H (2011) Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 33:505-522
9. Cysique LA, Brew BJ (2011) Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 17:176-183
10. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J, EuroSIDA Study Group (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55:320-328
11. D'Elia LF, Satz P, Uchiyama CL, White T (1996) Color Trail test. Professional manual. Psychological Assessment Resources, Odessa
12. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13:1249-1253
13. El-Sadr W, Lundgren J, Neaton J, Gordin F, Abrams D, Arduino R, Babiker A, Burman W, Clumeck N, Cohen C, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Mejia J, Markowitz N, Neuhaus J, Phillips A, Rappoport C, Antiretrovir SM (2006) CD4+ count-guided interruption of antiretroviral treatment. N Eng J Med 355:2283-2296
14. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087-2096
15. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
16. Heaton RK, Miller SW, Taylor JJ, Grant I (2004) Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African Americans and Caucasian adults. PAR Psychological Assessment Resources, Inc., Lutz
17. Heilbronner RL, Sweet JJ, Attix DK, Krull KR, Henry GK, Hart RP (2010) Official position of the American Academy of Clinical Neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. Clin Neuropsychol 24:1267-1278
18. Klove H (1963) Clinical neuropsychology. Saunders, New York
19. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, Kronborg G, Larsen CS, Obel N (2011) Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 52:235-243
20. Letendre SL, FitzSimons C, Ellis RJ, Clifford D, Collier AC, Gelman B, McArthur J, Vaida F, Heaton R, Grant I, the CHARTER Group (2010) Correlates of CSF viral loads in 1221 volunteers of the CHARTER cohort. In: Proceedings of the 17th Conference on Retrovirus and Opportunistic Infections, San Francisco, CA
21. Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA (2004) Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol 18:373-384
22. Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, Letendre S, Ellis RJ, Wallace MR, Heaton RK, Grant I (2003) Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 60:1406-1412
23. McArthur JC (2004) HIV dementia: an evolving disease. J Neuroimmunol 157:3-10
24. McArthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699-714
25. McCaffrey RJ, Duff K, Westervelt HJ (2000) Practitioner's guide to evaluating change with neuropsychological assessment instruments, 1st edn. Springer, New York
26. Morey LC (2006) PAI® software portfolio. PAR Psychological Assessment Resources, Inc., Lutz
27. Price RW, Yiannoutsos CT, Clifford DB et al (1999) Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 13:1677-1685
28. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P (1988) The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 239:586-592
29. R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
30. Reitan RM (1969) Manual for administration of neuropsychological test batteries for adults and children. Reitan, Indianapolis
31. Robertson KR, Parsons TD, Sidtis JJ, Inman TH, Robertson WT, Hall CD, Price RW (2006) Timed Gait test: normative data for the assessment of the AIDS dementia complex. J Clin Exp Neuropsychol 28:1053-1064
32. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acqu Imm Def Synd: JAIDS 36:562-566
33. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, Skiest DJ, Team AS (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260-1266
34. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, Mc Arthur JC, Study MAC (2001) HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56:257-260
35. Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E (2006). Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67:311-314
36. Sacktor N, Nakasujja N, Skolasky RL, Robertson K, Musisi S, Ronald A, Katabira E, Clifford DB (2009) Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 72:165-170
37. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A (1999) Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13:1889-1897
38. Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G (2001) Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acqu Imm Def Synd: JAIDS 28:19-27
39. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acqu Imm Def Synd: JAIDS 52:56-63 (Erratum appears in J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529)
40. Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, Pau FM, Pigorini F, Volpini V, Camporiondo MP et al (1993) Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 7:683-692
41. Winston A, Duncombe C, Li PCK, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA, Altair Study Group (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50:920-929 (Erratum appears in Clin Infect Dis. 2010 Sep 1;51(5):638)
42. Wright E (2011) Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS 6:303-308
43. Wright E, Grund B, Robertson K, Brew B, Roediger M, Bain M, Drummond F, Vjecha M, Hoy J, Miller C, de Oliveira A, Pumpradit W, Shlay J, El-Sadr W, Price R, Grp ISS (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864-873